Muscle

MUELLER SPORTS MEDICINE SIGNS AGREEMENT WITH FOOTBALL HALL OF FAMER DONALD DRIVER TO PROMOTE REVIVE COMPRESSION TECHNOLOGY

Retrieved on: 
Tuesday, December 20, 2022
Muscle, Knee, Green Bay Packers Hall of Fame, Mueller, Quenching, Sports medicine, Health, University, University of Wisconsin–Madison, Life, Green, X-ray, Brace, Human, Dance, Patent, Athlete, Metabolism, Skin, NFL, Sport, Toy

PRAIRIE DU SAC, Wis., Dec. 20, 2022 /PRNewswire/ -- Mueller Sports Medicine has signed an agreement with Green Bay Packers Hall of Famer Donald Driver, a football fan favorite and owner of Driven Elite Fitness & Health.

Key Points: 
  • PRAIRIE DU SAC, Wis., Dec. 20, 2022 /PRNewswire/ -- Mueller Sports Medicine has signed an agreement with Green Bay Packers Hall of Famer Donald Driver, a football fan favorite and owner of Driven Elite Fitness & Health.
  • "Since establishing Mueller Sports in 1959 - 63 years ago - we have been very protective of our family-owned brand," said John Cayer, President at Mueller.
  • "I am excited to bring Mueller Sports Medicine's products, especially the new REVIVE compression technology, to our award-winning personal training recovery lounges in each of our locations.
  • Mueller Sports Medicine, Inc. was founded more than 60 years ago by former University of Wisconsin basketball player turned registered pharmacist, Curt Mueller, who coined the term "sports medicine."

InventHelp Inventor Develops Fitness System for Beds (JMT-171)

Retrieved on: 
Monday, December 19, 2022
BED, Joint, Muscle, Sale, Multimedia, Sleep, 3D printing

PITTSBURGH, Dec. 19, 2022 /PRNewswire/ -- "I thought there should be a fitness system that enables you to engage in a full-body workout while in bed," said an inventor, from Christiansted, St. Croix, Virgin Islands, "so I invented the BED GYM.

Key Points: 
  • PITTSBURGH, Dec. 19, 2022 /PRNewswire/ -- "I thought there should be a fitness system that enables you to engage in a full-body workout while in bed," said an inventor, from Christiansted, St. Croix, Virgin Islands, "so I invented the BED GYM.
  • The patent-pending invention provides a low-impact gym system for the joints.
  • In doing so, it offers an effective way to engage in strength-training exercises while in bed.
  • 21-JMT-171, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

SummaForte(TM) Earns Coveted Presentation Slot At Florida Venture Summit

Retrieved on: 
Tuesday, December 6, 2022
CBN, Nutrient, Science and technology in Asia, Muscle, Medtech, Inflammation, Health, Menthol, Ligament, Lutein, Organization, USA Triathlon, Athlete, Major League Baseball, Dietary supplement, CBD

Miami, Florida--(Newsfile Corp. - December 6, 2022) - SummaForte recently became one of only 200 companies worldwide to earn a presentation slot at the 1st annual Florida Venture Summit.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - December 6, 2022) - SummaForte recently became one of only 200 companies worldwide to earn a presentation slot at the 1st annual Florida Venture Summit.
  • Using innovative processing and delivery technologies such as kinesiology tape that delivers menthol and CBD, SummaForte's products enhance performance and speed recovery.
  • The Miami-based Florida Venture Summit connects founders of the hottest venture-backed, emerging and early-stage companies with an exclusive audience of venture capitalists, corporate investors, private investors, and investment bankers in tech, fintech, cleantech, medtech, life sciences, and healthcare.
  • The presentation programs are geared toward emerging growth companies looking to gain visibility among active investors and raise capital.

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

Retrieved on: 
Friday, December 16, 2022
Lysosome, European Medicines Agency, European Commission, CHMP, Physician, Cell, NAS, EMA, Muscle, Annual report, Glycogen storage disease type II, BIS, Trial of the century, M6P, ERT, Amicus Therapeutics, Tissue, Glycogen storage disease, PROPEL, Infant, Glycogen, Committee for Medicinal Products for Human Use, Committee, Patient, EC, Disease, Therapy, Royal commission, Enzyme replacement therapy, Degenerative disease, Blood, Miglustat, Compte rendu, GAA, Skeletal muscle, Vaccine, Pharmaceutical industry, Dietary supplement, EU, Neurology

PHILADELPHIA, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of cipaglucosidase alfa, a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD). A decision from the European Commission (EC) on cipaglucosidase alfa, the enzyme replacement therapy component of AT-GAA, is expected in the first quarter of 2023. Cipaglucosidase alfa will be commercialized under the brand name POMBILITI™. The Company expects a CHMP opinion of miglustat, the enzyme stabilizer component of AT-GAA, in the second quarter of 2023.

Key Points: 
  • The Company expects a CHMP opinion of miglustat, the enzyme stabilizer component of AT-GAA, in the second quarter of 2023.
  • Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA).
  • Disease severity ranges on a spectrum, but predominant manifestations are skeletal muscle weakness and progressive respiratory involvement.
  • “Today’s positive CHMP opinion for Pombiliti™ (cipaglucosidase alfa) is a significant milestone and major step towards bringing this much needed new treatment for all adults living in the EU with late-onset Pompe disease.

uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B

Retrieved on: 
Friday, December 16, 2022
Observation, European Medicines Agency, European Commission, CHMP, Bleeding, EMA, Swelling, Protein, CMA, Muscle, Diagnosis, Patient, Partnership, ASX, Factor IX, Food, Lance, FIX, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ABR, Pain, Committee for Medicinal Products for Human Use, Committee, Joint, Advanced Therapy Medicinal Product, AAV, Padua, Haemophilia, Royal commission, Haemophilia B, CSL, Medical device, Pharmaceutical industry

Etranacogene dezaparvovec is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds after a single infusion.1,2 uniQure conducted the multi-year clinical development program for etranacogene dezaparvovec and will leverage its leading gene therapy manufacturing capabilities to supply CSL for commercialization.

Key Points: 
  • Etranacogene dezaparvovec is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds after a single infusion.1,2 uniQure conducted the multi-year clinical development program for etranacogene dezaparvovec and will leverage its leading gene therapy manufacturing capabilities to supply CSL for commercialization.
  • “We are very pleased with this positive opinion recommending conditional marketing authorization for etranacogene dezaparvovec,” said Matt Kapusta , chief executive officer of uniQure.
  • “The program’s multi-year clinical journey began in Europe with our first-in-human Phase I/II study, and the favorable CHMP opinion moves etranacogene dezaparvovec one step closer to the European hemophilia B community.
  • Etranacogene dezaparvovec is an adeno-associated virus five (AAV5)-based gene therapy given as a one-time treatment for moderately severe to severe hemophilia B patients.

Oxford Biomedica Solutions forms new partnerships with three biotechnology companies

Retrieved on: 
Wednesday, December 14, 2022
CNS, Bioreactor, Muscle, CTAS, Drug development, AAV, Growth, 104th Street station (IND Fulton Street Line), Autoimmunity, Chair, Patient, Fine chemical, Online shopping

BEDFORD, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced today that it has signed agreements with three additional U.S. based, biotechnology companies.

Key Points: 
  • BEDFORD, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced today that it has signed agreements with three additional U.S. based, biotechnology companies.
  • This places Oxford Biomedica Solutions ahead of the previously stated target of two new partners by the end of the calendar year.
  • Oxford Biomedica Solutions’ proven platform has demonstrated consistent bioreactor titers of E15 vg/L and achieved over 90% fully intact vector for multiple constructs.
  • Oxford Biomedica Solutions’ innovative platform potentially enables accelerated drug development of high quality products produced at significantly more doses per batch.

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product

Retrieved on: 
Wednesday, December 14, 2022
RHO, Fibromyalgia, Associate, Absorption, Science, Cannabis, Formulary, Toronto Stock Exchange, FSE, Dermatology, Terpene, Research, Rheumatoid arthritis, Nursing, Clinical trial, Inflammation, Chronic pain, McGill University, Wellness, Risk, CRS, TSX, R, Quality of life, CBG, News, Overalls, CBD, Social media, Patient, Data collection, Physician, Offering, Menthol, Cannabinoid, Eugenol, Muscle, Medical Affairs Bureau, SEDAR, Osteoarthritis, Arthritis, Medical device, Drug, Medicine, Pharmaceutical industry, Cannabigerol, Cannabidiol

The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment.

Key Points: 
  • The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment.
  • The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider.
  • Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO.
  • The gel includes a combination of CBG and CBD in a fast-absorbing, water-based gel intended for application locally to area of focus.

New West Dental Lab Introduces EndSnorZ™ Sleep Appliance

Retrieved on: 
Monday, December 12, 2022
Mads, CDT, Sleep apnea, Muscle, Dentist, Bridge, Sleep, MAD, Vibration, Traction, Orientation, Ligament, Patient, The Closed Mouth, Mouth, Snoring, OSA, Tissue, Success, Dentistry, New West Records

LAKE HAVASU CITY, Ariz., Dec. 12, 2022 (GLOBE NEWSWIRE) -- New West Dental Lab, a full-service dental laboratory that has been serving dentists nationally for over 40 years, has announced a new addition to its family of mandibular advancement devices (MADs), the EndSnorZ™ Sleep Appliance.

Key Points: 
  • LAKE HAVASU CITY, Ariz., Dec. 12, 2022 (GLOBE NEWSWIRE) -- New West Dental Lab, a full-service dental laboratory that has been serving dentists nationally for over 40 years, has announced a new addition to its family of mandibular advancement devices (MADs), the EndSnorZ™ Sleep Appliance.
  • Dentists who trust New West with their crown & bridge restorations will find the EndSnorZ to be a reliable and precise 3D-printed appliance that fits well with the high-quality standards that the dental treatment of snoring and sleep apnea demands.
  • "I'm pleased to announce the availability of the EndSnorZ Sleep Appliance," said New West General Manager Hollie Taylor, CDT.
  • In its four decades of serving dentists across the country, New West Dental Lab has worked very closely with dental teams and vendor groups to provide an elevated patient experience.

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

Retrieved on: 
Wednesday, December 7, 2022
PGN, Liver, Peptide, Cell, RPLP0, Muscle, Clinical trial, GLP, CNS, Kidney, Marketing, Safety, Heart, CUG, DMPK, EDO, Disability, DM1, Toxicology, Research, Disease, IND, CTG, Risk, Myotonia, Patient, Therapy, Real-time, Fine chemical, Vaccine, Pharmaceutical industry

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced new preclinical data supporting the progression of PGN-EDODM1, PepGen’s product candidate in development for the treatment of myotonic dystrophy type 1 (DM1), into clinical trials. PGN-EDODM1 leverages PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology and consists of the Company’s proprietary cell-penetrating peptide conjugated to a steric blocking oligonucleotide cargo. This well-characterized therapeutic oligonucleotide is designed to bind to the CUG repeat expansion hairpin loops in the DMPK transcripts of people with DM1, and thus subsequently correct the downstream transcript mis-splicing events that lead to myotonia and cardiac dysfunction.

Key Points: 
  • “We are now pleased to provide an update on the safety profile of PGN-EDODM1, having completed IND-enabling preclinical studies in multiple models.
  • Notably, we observed that this product candidate was well-tolerated in acute GLP studies conducted in rodents and NHPs at what we believe are clinically relevant doses.
  • We believe that the totality of the data obtained from these preclinical and IND-enabling studies highlights a potentially favorable safety profile for PGN-EDODM1.
  • PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Incannex Expands Intellectual Property Position over IHL-42X

Retrieved on: 
Tuesday, December 6, 2022
Government budget balance, Accident, Associate, Depression, Sleep, Muscle, Clinical trial, Patent Cooperation Treaty, Incidence, Irritability, ASX, Cardiovascular disease, Obstructive sleep apnea, Hypertension, Continuous positive airway pressure, Fatigue, Sleep-related breathing disorder, THC, US, Dronabinol, Physiology, University, Polysomnography, AHI, Acetazolamide, Loop gain, Metabolic acidosis, CPAP, Research, Apnea–hypopnea index, Patent, Risk, Blood, Finswimming at the 2017 World Games – Men's 50 m apnoea, Patient, Monash University, Anxiety, Pharmaceutical industry, Medical device

Dronabinol is believed to activate muscles in the upper airway during sleep, thereby reducing incidence of airway collapse.

Key Points: 
  • Dronabinol is believed to activate muscles in the upper airway during sleep, thereby reducing incidence of airway collapse.
  • Incannex previously discovered that the two drugs act synergistically to reduce the Apnea Hypopnea Index (AHI) in patients with OSA.
  • CEO and Managing Director of Incannex Healthcare, Mr Joel Latham said; “Incannex works closely with its patent attorneys to build upon its competitive position through the ongoing development of intellectual property assets.
  • Results from a Phase 2 proof of concept clinical trial undertaken by Incannex were published in 2022.